Migraine
Migraine is a genetically influenced complex neurological disorder marked by moderate-to-severe, often unilateral headaches accompanied by nausea, sensitivity to light and sound, and exacerbation with physical activity; it is more prevalent in women and can involve additional symptoms such as vomiting, cognitive dysfunction, and dizziness. Characterized by its episodic or chronic nature, migraines can also include aura, a sensory disturbance experienced by up to one-third of sufferers.
Health Outcomes
- Absence of Serious Adverse Events
- Absence of Severe Adverse Reactions
- Achieved Complete Symptom Cessation
- Altered Endocannabinoid System Function Due to Specific Strain
- Altered Pyridoxine Concentration
- Comparable Tolerability
- Enhanced Host Well-being
- Enhanced Placebo Response
- Formation of Biogenic Amines
- Global Relief Assessment
- Improved Capsaicin Tolerance
- Improved Cerebral Blood Flow Velocity
- Improved Feeling of Well-being
- Improved Global Symptom
- Improved Headache-Related Quality of Life
- Improved Health-related Quality of Life
- Improved Migraine
- Improved Migraine-Specific Quality of Life
- Improved Neurological Health
- Improved Neurological Symptoms
- Improved Neurotransmitter Profile
- Improved Overall Symptom Relief
- Improved Overall Symptoms
- Improved Pain Intensity
- Improved Pain Management
- Improved Pain Scale
- Improved Pain Score
- Improved Pain Threshold
- Improved Presenteeism
- Improved Productive Performance
- Improved Secondary Symptoms
- Improved Serotonin Metabolism
- Improved Symptom Control
- Improved Symptom Relief
- Improved Symptom Resolution
- Improved Symptom Score
- Improved Symptoms
- Improved Work Performance
- Increased 5-Hydroxytryptophan Levels
- Increased Analgesic Capacity
- Increased GABAergic Signaling
- Increased Headache
- Increased Irritability
- Increased Pain
- Increased Pain-Free Days
- Increased Perceived Pain
- Increased Production of Biogenic Amines
- Increased Serotonin Levels
- Increased Treatment Effectiveness
- Increased Treatment Response
- Increased Tyramine Production
- Modulated Nociceptive Signaling
- Nervous System Dysfunction in Host
- Neutral Blood Profile Impact
- No Change in Anxiety
- No Change in Negative Mood States
- Prevention of Neurological Disorders
- Reduced Analgesic Usage
- Reduced Analgesic Use
- Reduced Antiemetic Medication Use
- Reduced Average Pain
- Reduced Bodily Pain
- Reduced Central Nervous System Symptom Severity
- Reduced Clinical Disease Signs
- Reduced Cortical Spreading Depression
- Reduced Daily Episode Severity
- Reduced Daily Life Disturbance
- Reduced Day School Absenteeism
- Reduced Digital Eye Strain Symptoms
- Reduced Discomfort
- Reduced Disease Symptoms
- Reduced Episode Frequency
- Reduced Headache
- Reduced Headache Duration
- Reduced Headache Frequency
- Reduced Headache Impact Score
- Reduced Headache Pain Intensity
- Reduced Headache Severity
- Reduced Interference Score
- Reduced Interference with Daily Life
- Reduced Levels of Pro-Inflammatory Cytokines (IL-1β, IL-6, IFN-γ, TNF-α)
- Reduced Migraine Duration
- Reduced Migraine Frequency
- Reduced Migraine Neural Hyperexcitability
- Reduced Migraine Severity
- Reduced Nausea Severity
- Reduced Nausea Symptom Severity
- Reduced Nausea and Vomiting
- Reduced Neurological Symptoms
- Reduced Opioid Consumption
- Reduced Overall Symptom Score
- Reduced Overall Symptoms
- Reduced Pain
- Reduced Pain Assessment Score
- Reduced Pain Frequency
- Reduced Pain Intensity
- Reduced Pain Levels
- Reduced Pain Scale
- Reduced Pain Score
- Reduced Pain Sensitivity
- Reduced Pain Severity
- Reduced Pain Symptom Score
- Reduced Pain Symptoms
- Reduced Pain-Related Disability
- Reduced Painkiller Consumption
- Reduced Peripheral Sensitization
- Reduced Photophobia
- Reduced Photophobia Symptom Score
- Reduced Physical Symptoms
- Reduced Physical Symptoms of Stress
- Reduced Severity of Symptoms Per Day
- Reduced Standard Care Medication Need
- Reduced Subjective Symptoms
- Reduced Substance P Levels
- Reduced Symptom Severity
- Reduced Symptom Severity Scale Score
- Reduced Symptoms
- Reduced TRPV1 Activation
- Reduced Total Analgesic Dosage
- Reduced Total Symptom Score
- Reduced Trigeminal Neuron Excitability
- Reduced Worst Pain
- Safety Comparable to Control
- Symptom Alleviation
- Unchanged Symptom Severity
- Well-Tolerated Supplementation